'Ceprotin' has entered the last stage of obtaininig reimbursement listing.

According to our investigation, Takeda Pharmaceuticals Korea has started to negotiate drug pricing with the National Health Insurance Service (NHIS) for Ceprotin (Human potein C), a novel drug for the treatment of congenital protein C deficiency.

‘Human protein C deficiency’ is a type of thrombotic disease that causes blood clotting and it was first reported in 1981. 'Severe congenital protein C deficiency,' a type of protein C deficiency, is an extremely rare disease that occurs in one in every 4 million. In South Korea, there have been reported cases of 13 patients to date (according to 2019 KOSIS statistics)